TG103、HER2 双抗、白紫II 等新品重磅有望26 年获批上市，贡献收入增量。 EGFR ADC：海内外临床稳步推进，看好重磅出海潜力我们看好EGFR ADC 年内国内+海外积极开启三 期：1）国内临床：积极拓展EGFR 突变二线III 期、联合奥希替尼突变一线Ib 随访中，有望年内III期， 及联合PD-1 野生型一线II 期，头颈鳞癌/食管鳞癌在策划一线三期：2）海外临床进展：NSCLC 经典突 变三线及野生型2L+为重点。我们认为EGFRADC 依旧是海内外从数据质量、入组人数及临床进展均具 备竞争力的ADC管线，看好年底到1H26 出海潜力。 机构：华泰证券 研究员：代雯/沈卢庆/孙茗馨 公司公告，实现1-3Q25 收入198.9 亿元（-12.3%yoy，3Q 收入+3.4%yoy，+5.7%qoq），归母净利润35.1 亿元（-7.1%yoy，3Q 利润+27%yoy）；其中3Q25 利润为9.6 亿元（我们估测近6 亿内生利润）。公司 3Q25 收入重回增长，主因：1）成药业务剔除授权收入降幅缩窄，多美素集采影响逐步消散；2）期内 确认与阿斯利康AI 平台及部分Lp（a）小分子BD 合作的 ...

Investment Rating - The report maintains an investment rating of "Buy" for the company with a target price of HKD 12.75 [7]. Core Views - The company achieved a revenue of RMB 19.89 billion for the first three quarters of 2025, representing a year-over-year decline of 12.3%, but a growth of 3.4% year-over-year in Q3 [1]. - The net profit attributable to the parent company for the first three quarters was RMB 3.51 billion, down 7.1% year-over-year, with Q3 profit showing a significant increase of 27% year-over-year [1]. - The revenue growth in Q3 is attributed to the narrowing decline in the prescription drug business and the gradual dissipation of the impact from centralized procurement [1][2]. - The company is optimistic about the continued market expansion of new products such as Omaguzumab and Mingfule under the backdrop of ongoing market development [1][2]. Summary by Sections Revenue and Profitability - The company reported a revenue of RMB 19.89 billion for 1-3Q25, with Q3 revenue showing a 3.4% year-over-year increase and a 5.7% quarter-over-quarter increase [1]. - The net profit for 1-3Q25 was RMB 3.51 billion, with Q3 profit at RMB 960 million, indicating a strong recovery in profitability [1]. Product Pipeline and Business Development - The report highlights the potential of the EGFR ADC pipeline, with ongoing clinical trials both domestically and internationally, indicating strong competitive advantages [3]. - The company confirmed BD revenue of RMB 1.54 billion in 1-3Q25, with expectations for continued BD opportunities in 2026 [4]. Future Outlook - The company anticipates a return to positive growth in prescription drug revenue by 2026, driven by new product launches and the absence of major products in the latest round of centralized procurement [2]. - The projected net profits for 2025-2027 are RMB 4.55 billion, RMB 4.63 billion, and RMB 5.03 billion respectively, with corresponding EPS estimates of RMB 0.40, RMB 0.40, and RMB 0.44 [5][10].

Core Viewpoint - The company reported a significant improvement in revenue and profit in Q1 2025, driven by stable core business performance and the recognition of upfront payments from Lp(a) and MAT2A small molecule BD transactions [1][2]. Group 1: Financial Performance - Q1 2025 revenue reached 7.015 billion yuan, representing a year-on-year decline of 21.9% but a quarter-on-quarter increase of 11% [1]. - Net profit attributable to the parent company was 1.48 billion yuan, down 8.4% year-on-year but up 169% quarter-on-quarter [1]. - The improvement in revenue and profit was attributed to the confirmation of upfront payments from BD transactions and a stabilization in core business revenue [2]. Group 2: Business Development and Pipeline - The company is optimistic about the EGFR ADC clinical trials, with five Phase III trials expected to be conducted domestically and internationally this year [2]. - Positive data from AACR regarding lung cancer overall response rate (ORR) and safety profiles were highlighted, indicating strong potential for market entry [2]. - The company is focusing on HER2-targeted therapies and anticipates the launch of GLP-1 products by 2026 [3]. Group 3: Cost Management and Future Outlook - The company has significantly reduced sales expenses, with a sales expense ratio of 24% in Q1 2025 compared to 33% in Q1 2024 [2]. - The company expects a gradual improvement in revenue and profit throughout 2025, with a conservative estimate of approximately 4 billion yuan in core business profit for the year [2]. - The target price for the company's stock is set at 10.12 HKD, based on a 19x PE ratio for 2025 [3].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 10.12 HKD [8][9]. Core Views - The company reported a significant quarter-on-quarter improvement in 1Q25, with revenue of 7.015 billion RMB (-21.9% year-on-year, +11% quarter-on-quarter) and a net profit of 1.48 billion RMB (-8.4% year-on-year, +169% quarter-on-quarter) [1]. - Key drivers for the positive performance include the stabilization of core business and the recognition of upfront payments from Lp(a) and MAT2A small molecule BD transactions [2]. - The company is expected to see a gradual improvement in revenue and profit throughout the year, driven by the inventory cycle and new product launches [2]. - The EGFR ADC clinical trials are progressing rapidly, with promising data expected to enhance the company's international potential [3]. - The company is focusing on innovative pipelines, including HER2-targeted therapies and GLP-1 analogs, with expected market entries in the coming years [4]. Financial Projections - The company forecasts EPS of 0.49, 0.50, and 0.57 RMB for 2025, 2026, and 2027 respectively, with a target price based on a 19x PE ratio for 2025 [5]. - Revenue projections for 2025 are estimated at 31.101 billion RMB, with a conservative estimate of approximately 4 billion RMB in net profit for the year [2][19]. - The report anticipates a steady increase in revenue and profit margins, with a projected net profit margin of 18.31% for 2025 [19].